The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011.
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Ronald De Wit
Honoraria - Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Bayer; Clovis Oncology; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lilly
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Clovis Oncology; Eisai; Sanofi; Targeted Oncology
Speakers' Bureau - Bayer; Merck; Sanofi; Sanofi/Aventis
Research Funding - Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (I); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Eisai; Janssen; Medivation/Astellas; Merck; Sanofi
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
 
Eric Sbar
Employment - Merck Sharp & Dohme; Pfizer
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Research Funding - Merck Sharp & Dohme; Pfizer
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer
 
Xieyang Calvin Jia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Corina E. Dutcus
Employment - Eisai
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.